Podcast brought to you by: Genia Technologies - Makers of integrated circuits for "Last Gen" DNA sequencing. Biology . . . meet the integrated circuit.
Deborah Kilpatrick, VP of Commercial, CardioDx Bio and Contact Info
Chapters: (Advance the marker)
0:40 Corus CAD™ - a diagnostic for a "huge cardiovascular market"
6:31 CardioDx - fusion between biotech, med device, high tech, and specialty pharma
10:11 The successful path toward reimbursement coverage
18:00 With Medicare approval and new funding, what is your focus now?
20:01 Diagnostics an answer to a troubled healthcare system
25:17 Selling to doctors with misaligned incentives
29:30 Personal journey from defense to diagnostics
Today we begin a series of shows about Commercializing Diagnostics. And we've chosen a company with some successes and great potential, CardioDx, based in Palo Alto, CA. They recently won Medicare coverage for their Corus CAD(™) test which can tell whether a blockage in your heart is causing symptoms such as chest pain or tiredness.
The challenge for diagnostic companies, according to Chief Commercial Officer, Deb Kilpatrick, is in demonstrating with data that the test is better than current methods. In this interview, Deb outlines the path that CardioDx took toward reimbursement and offers her insight for others pursuing what has become the holy grail for diagnostics companies. Indeed, there is now a conference devoted just to this issue of reimbursement. What next for CardioDx, we ask Deborah. This leads to a discussion about the role diagnostics companies can play in the challenges facing the healthcare system today. Will there be 'big diagnostics' along side 'big pharma?'